FDA accepted an RTOR sBLA and granted priority review for zanidatamab-hrii combinations as first-line therapy in HER2+ ...

Rusfertide may reduce phlebotomy needs in polycythemia vera, offering a convenient weekly self-injection option that could ...

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse ...

A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast ...

The investigational agent IMNN-001 is demonstrating promising potential to extend survival in patients with advanced ovarian ...

Rashmi Chugh, MD, of the University of Michigan, outlines a strategic roadmap for the future development of ozekibart in ...

As Dr Wang explains, the combination of robust efficacy, manageable toxicity, and longer follow-up—along with pooled data ...

During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.

In this phase 1 trial (NCT03715933), ozekibart is paired with the established chemotherapy duo of temozolomide and irinotecan ...

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides ...

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...

Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient ...